Present and future of renal transplantation;Presente y futuro del trasplante renal

Actas Urologicas Espanolas

Volumn 26, Issue 10, 2002, Pages 731-758

  Burgos, F J ^a,b   Alcaraz, A ^c   Castillon I ^d   Gonzalez Martin M ^e   Lledo E ^f   Matesanz, R ^a,g   Marcen R ^a,b   Montanes P ^h,i   Pascual, J ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c FUNDACIÓ PUIGVERT   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g Nacional de Trasplante ONT   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ Hospital Virgen del Rocío ^*  (Spain)

Author keywords

Donation; Inmunosuppression; Preservation; Renal transplant; Xenotransplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS;

ARTICLE; CADAVER DONOR; CANCER RISK; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY PRESERVATION; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHOMA; POSTOPERATIVE COMPLICATION; SKIN CANCER; XENOTRANSPLANTATION;

EID: 0036879567     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-4806(02)72853-2     Document Type: Article

References (92)

1. CANAFAX DM, TORRES A, FRYD DS et al.: The effects of delayed function on recipients of cadaver renal allografts. Transplantation 1986; 41: 187-200.
2. SACKS SA, PETRITSCH PH, KAUFMAN et al.: Canine kidney preservation using a new perfusate. Lancet 1973; 1: 1.024-1.026.
3. ALCARAZ, A, LUQUE, P, MENDES, D et al.: Experimental kidney transplantation in pigs from non-heart-beating donors. Evaluation of vasoactives substances and renal artery flow. Transp Proc 2001; 32: 198-199.
4. COLLINS GM, HALASZ NA.: Composition of intracellular flush solutions for hypotermic kidney storage. Lancet 1975; 1: 220-223.
5. PLOEG RJ, VAN BOCKEL JH, IANGENDIJK PT.: Effect of preservation solution on results of cadaveric kidney transplant. The European Multicenter study group. Lancet 1992; 340: 129-137.
6. WIEJNEN RM, BOOSTER MH, STUBENITSKY BM et al.: Outcome of transplantation of non-heart-beating donor kidneys. Lancet 1995; 345: 1.067-1.070.
7. VALERO R, CABRER C, OPPENHEIMER F et al.: Transpl Int 2000; 13: 303-310.
8. KOOSTRA G, KIEVIT JK, HIENEMAN E et al.: The non-heart-beating donor. Br Med Bull 1997; 53: 844-853.
9. DAEMEN JW, OOMEN AP, JANSEN MA et al.: Glutathione S-transferase as predictor of functional outcome in transplantetion of machine-preserved non-heart-beating donor kidneys. Transplantation 1997; 29: 1.378-1.380.
10. ALCOBERRO J, ALCARAZ A, áLVAREZ-VIJANDE R et al.: Experimental kidney transplantation in pigs from non-heart-beating donors: evaluation of renal artery flow. Transplant Proc 1999; 31: 2.348-2.349.
11. BALUPURI S, BUCKLEY P, MOHAMED M et al.: Assessment of non-heart-beating kidneys for viability on machine perfusion. Clin Chem Lab Med 2000; 38: 1.103-1.106.
12. LUQUE, áLVAREZ-VIJANDE R, ALCARAZ A et al. Experimental study of the cellular energy charge in kidney transplants with non-heart-beating donors. Transplant Proc 1999; 31: 2.352-2.353.
13. HENE RJ, VAN DER GROND J, BOER WH et al.: Pre-transplantation assessment of renal viability with 31P magnetic resonance spectroscopy. Kidney Int 1994; 46: 1.694-1.699.
14. LANGENDORFF O.: Untersuchungen am ukerlebenden Saugethierzen. Arch Ges Physiol 1895; 61: 291-332.
15. COYNE JA, RUDOLF LE, ALLPORT E et al.: Perfusion pressure and its relation to vascular resistance in isolated canine kidneys. In "Organ Perfusion and Preservation" (JC Norman ed). Appleton, Nueva York, 1968: 33-34.
16. BELZER FO, ASHBY BS, DUNPHY JE et al.: 24- and 72-hour preservation of canine kidneys. Lancet 1967; 2: 536-539.
17. SOUTHARD JH, SENZIG KA, HOFFMANN RM et al.: Toxicity of oxygen to mitochondrial respiratory activity in hypothermically perfused canine kidneys. Transplantation 1980; 29 (6): 459-461.
18. BOOSTER MH, WIJNEN RMH, YIN M.: Enhanced resistance to the effects of normothermic ischemia in kidneys using pulsatile machine perfusion. Transpl Proc 1993; 25 (6): 3.006-3.011.
19. BOOSTER MH, YIN M, STUBENITSKI BM et al.: Beneficial effect of machine perfusion on the preservation of renal microcirculatory integrity in ischemically damaged kidneys. Transpl Proc 1993; 25 (6): 3.012-3.016.
20. LIGHT JA, KOWALSKI RN, GAGE F.: Immediate function and cost comparison between ice storage and pilsatile preservation in kidney recipients at one hospital. Comunicaciónal I International Meeting on Non-Heart-Beating Donor Kidney Transplant. Maastricht, abril 1995.
21. MATSUNO N, KOZAKI M, SAKURAI E et al.: Effect of combination in situ cooling and machine perfusion preservation on non-heart-beating donor kidney procurement. Transpl Proc 1993; 25 (1): 1.516-1.517.
22. KOZAKI K, UCHIYAMA M, NEMOTO T et al.: Usefulness of continuous hypothermic perfusion preservation for renal grafts from non-heart-beating donors with prolonged warm ischemia time. Transplant Proc 1997; 29: 3.586-3.587.
23. KOYAMA H, CECKA JM, TERASACKI PI et al.: A comparison of cadaver kidney storage methods: pump perfusion and cold storage solutions. Clin Transplantation 1993; 7: 199-205.
24. OPELZ G, WUJCIAK T for the Collaborative Transplant Study. Comparative Analysis of kidney preservation methods. Transpl Proc 1996; 28: 87-90.
25. VAN DER VLIET JA, KIEVIT JK, HENE RJ et al.: Preservation of non-heart-beating donor kidneys: a clinical propective randomised case-control study of machine perfusion versus cold storage. Transpl Proc 2001; 33: 847.
26. BALUPURI S, STRONG A, HOERNICH N et al.: Machine perfusion for kidneys: how to do it at a minimal cost. Transpl Int 2001; 14: 103-107.
27. VALERO R, CABRER C, OPPENHEIMER F et al.: Normothermic recirculation reduces primary graft dysfunction of kidneys obtained from non-heart-beating donors. Transpl Int 2000; 13: 303-310.
28. DAEMEN JWHC, OOMEN APA, JANSSEN MA et al.: Gluthatione S-transferase as predictor of functional outcome in transplantation of machine-preserved non-heartbeating donor kidneys. Transplantation 1997; 63: 89-93.
29. MATSUNO N, MUTO S, UCHIYAMA M et al.: Beneficial effect of aspirin and protease inhibitor as graft conditioning using machine perfusion in warm ischemically injured kidneys. Transpl Proc 1997; 29: 3.584-3.585.
30. SAUNDER A, DANIELEWICZ R, AMETANI M et al.: L-Arginine in five-day perfusion of canine kidneys. Transpl Proc 1993; 25: 3.004-3.005.
31. CHINTALA MS, CHIU PJS, VEMULAPALLI S et al.: Inhibition of endothelial derived relaxing factor (EDRF) aggravates ischemic acute renal failure in anesthetized rats. Arch Pharmacol 1993; 348: 305-310.
32. HANSEN TN, D'ALESSANDRO A, SOUTHARD JH et al.: Reduced renal vascular injury following warm ischemia and preservation by hypothermic machine perfusion. Transpl Proc 1997; 29: 3.577-3.579.
33. RATNER LE, CISEK LJ, MOORE RG et al.: Laparoscopic live donor nephrectomy. Transplantation 1995; 60: 1.047-1.049.
34. FINELLI FC, GóNGORA E, SASAKI, TM et al.: A survey: the prevalence of laparoscopic donor nephrectomy at large U.S. Transplant centers. Transplantation 2000; 71: 1.862-1.864.
35. JACOBS SC, CHO E, DUNKIN BJ et al.: Laparoscopic live donor nephrectomy: the University of Maryland 3-year experience. J Urol 2000; 164: 1.494-1.499.
36. LEVENTHAL JR, DEEIK RK, JOEHL RJ et al.: Laparoscopic live donor nephrectomy - is it safe? Transplantation 2000 27; 70 (4): 602-606.
37. BROWN SL, BIEHL TR, RAWLINS MC et al.: Laparoscopic live donor nephrectomy: a comparison with the conventional open approach. J Urol 2001; 165: 766-769.
38. SASAKI TM, FINELLI F, BUGARIN E et al.: Is laparoscopic donor nephrectomy the new criterion standard? Arch Surg 2000; 135 (8): 943-947.
39. WOLF JS, MERION RM, LEICHTMAN AB et al.: Randomized controlled trial of hand-assisted laparoscopic versus open surgical live donor nephrectomy. Transplantation 2001; 72: 284-290.
40. STIFELMAN MD, HULL D, SOSA RE et al.: Hand assisted laparoscopic donor nephrectomy: a comparison with the open approach. J Urol 2001; 166: 444-448.
41. CASTILLóN VELA I, MARTíNEZ A, VAPNEK E et al.: Prospective non randomized study comparing laparoscopic donor nephrectomy (LDN), minimally invasive open donor nephrectomy (MIODN) and open donor nephrectomy (ODN). American Journal of Transplantation 2001; 1 (Suppl 1): S262.
42. CASTILLóN, VELA I, NARAGHI R, ASAI P et al.: Minimally invasive open donor nephrectomy (MIODN). American Journal of Transplantation 2001; 1 (Suppl 1): S66.
43. MONTAñéS P; SáNCHEZ E; TORRUBIA F.: Historia del trasplante renal. En: Complicaciones Quirúrgicas del Trasplante Renal. Edit. ENL. 2000: 25-28.
44. ROCHA JL.: Tesis Doctoral. Factores pronósticos en el trasplante renal. Universidad de Sevilla 1998.
45. CECKA JM, CHO YW, TERASAKI P et al.: Analyses of the UNOS scientific renal trasplant registry at three years-early events affecting trasplant success. Trasplantation 1992; 53: 59-64.
46. DESCAMPS B.: New insights into inmmunologic selection of human cadaver renal allograft recipients based on inmmune response capacities. Trasplant Proc 1978; 10: 497-499.
47. GJERTSON D.: Center dependent transplantation factors: an analysis of renal allografts reported to the UNOS registry. En Terasaki PI Edit.: Clinical Trasplant. UCLA tissue typing laboratory, Los Angeles 1993: 445-468.
48. CHO YW, CECKA JM.: Organ procurement organization and transplant center effects on cadaver renal transplant outcomes. En Terasaki PI (ED): Clinical Transplant. UCLA Tissue typing laboratory, Los Angeles 1996; 427-441.
49. CANDINAS D, SCHLUMPF R, RÖFHLIN MA.: Thrirty two years of renal trasplantation in Zurich. En Terasaky PI (ed). Clinical transplant UCLA Tissue Typing laboratory. Los Angeles 1996: 241-247.
50. TERASAKI PI, CECKA, GJERTSON DW.: Risk rate and long-term kidney transplant survival. En Terasaky; PI (ED): Clinical Transplant 1996. Tissue typing laboratory. Los Angeles: 443-458.
51. OJO AD, MEIER-KRIESCHE HU, HAUSON JA et al.: Mycophenolato mofetil recluses late renal allograft lose independent of acute rejection. Transplantation 2000; 69: 2.405-2.409.
52. DANOVITCH GM.: Immunosuppressive medications for renal transplantation. A multiple choice question. Kidney Int 2001; 59: 388-402.
53. PLOSKER GL, FOSTER RH.: Tacrolimus. Drugs 2000; 59: 323-389.
54. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999; 34: 296-303.
55. PASCUAL J, ORTUñO J.: Nuevos tratamientos inmunodepresores de inducción en el trasplante renal. Med Clin (Barc) 2001; 117: 147-157.
56. SAUNDERS RN, METCALFE MS, NICHOLSON ML.: Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59: 3-16.
57. MARGREITER R for the European tacrolimus vs ciclosporin microemulsion renal transplantation study group. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: a randomised multicentre study, Lancet 2002; 359: 741-746.
58. PASCUAL J, MARCéN R, BURGOS FJ y cols.: One-center comparison between primary immunosuppression based on neoral cyclosporine and tacrolimus for renal transplantation. Transplant Proc 2002 (en prensa).
59. ASHAN N, JOHNSON C, GONWAT y cols.: Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution plus mycophenolate mofetil after cadaveric renal transplantation: results after 2 years. Transplantation 2001; 72: 245-250.
60. FERNáNDEZ-JUáREZ G, PASCUAL J, MARCéN R y cols.: Retrasplante renal en enfermos tratados con ciclosporina. Nefrología 1999; 19: 61-66.
61. PENN I.: Donor transmitted disease: cancer. Transplant Proc 1990; 23: 2.629-2.631.
62. FERNáNDEZ-LUCAS M, MATESANZ R.: Estandarización en los criterios de donación de órganos para prevenir la transmisión de enfermedades neoplásicas. Documento internacional de consenso. Rev Esp Trasp 1997; 6: 8-16.
63. PENN I.: Malignancy in transplanted organs. Transpl Int 1993; 6: 1-3.
64. The EBPG expert group on renal transplantation. European best practice guidelines for renal transplantation (Part I). Evaluation and selection of donors. Nephrol Dial Transplant 2000; 15 (suppl 7): 39-51.
65. CHUI AKK, HERBERTT K, WANG LS et al. Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report. Transplant Proc 1999; 31: 1.266-1.267.
66. KASISKE BL, RAMOS EL, GASTON RS et al.: The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Educational Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1995; 6: 1-34.
67. PENN I.: The effect of immunosuppression on pre-existing cancers. Transplantation 1993; 55: 742-747.
68. The EBPG expert group on renal transplantation. European best practice guidelines for renal transplantation (Part I). Evaluation, selection and preparation of the potential transplant recipient. Nephrol Dial Transplant 2000; 15 (suppl 7): 1-38.
69. PENN I: Postransplant malignancies. Transplant Proc 1999; 31: 1.260-1.262.
70. FELIPE C, MARCéN R, NAYA MT, MORENO R, OROFINO L, ORTUñO J.: Neoplasias en insuficiencia renal crónica. Nefrología 1993; 13: 30-36.
71. GóMEZ V, BURGOS FJ, PASCUAL J y cols.: Prevalencia de neoplasias en el trasplante renal. Arch Esp Urol 1997; 50: 267-273.
72. SHEIL AGR.: Patterns malignancies following renal transplantation. Transplant Proc 1999; 31: 1.263-1.265.
73. HERMIDA JJ, MORENO J, BLáZQUEZ J y cols.: Incidencia de neoplasias en pacientes con trasplante renal. ¿Está cambiando el patrón de neoplasias en estos pacientes?. Arch Esp Urol 1998; 51: 683-691.
74. OPELZ G, HENDERSON R.: Incidence of nonHodking lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1.514-1.516.
75. BAVINCK JNB, HARDIE DR, GREEN A et al.: The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation 1996; 61: 715-721.
76. PENN I.: Cancer in cyclosporine-treated vs azathioprine-treated patients. Transpl Proc 1996; 28: 876-878.
77. NEWSTEAD CG.: Lymphoproliferative disease post-renal transplantation. Nephrol Dial Transplant 2000; 15: 1.913-1.916.
78. SHEIL AGR, DISNEY APS, MATHEW TH et al.: Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following transplantation. Transplant Proc 1997; 29: 825-827.
79. PASCUAL J, TORRELO A, TERUEL JL et al.: Cutaneous T cell lymphomas after renal transplantation. Transplantation 1992; 53: 1.143-1.145.
80. FRANCES C.: Kaposi's sarcoma after renal transplantation. Nephrol Dial Transplant 1997; 13: 2.768-2.773.
81. PEN I.: Sarcomas in organ allograft recipients. Transplantation 1995; 60: 1.485-1.491.
82. MARCéN R, PASCUAL J, SERRANO P et al.: Renal cell carcinoma of the native kidney in a female renal allograft patient without acquired cystic kidney disease. Nephron 1992; 61: 238-239.
83. BUZZEO BD, HEISEY DM, MESSING EM: Bladder cancer in renal transplant recipients. Urology 1997; 50: 525-528.
84. KONETY BR, TEWARI A, HOWARD RJ et al.: Prostate cancer in the post-transplant population. Urology 1998; 52: 428-432.
85. BRUNNER FP, LANDAIS P, SELWOOD NH: Malignancies after renal transplantation: the EDTA-ERA Registry experience. Nephrol Dial Transplant 1995; 10 (suppl 1): 74-80.
86. WINAWER SJ, FLETCHER RH, MILLER L et al.: Colonorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642.
87. LEITCH AM, DODD GD, COSTANZA M et al.: American Cancer Society guidelines for the early detection of breast cancer: update 1997. CA Cancer J Clin 1997; 47: 150-153.
88. MAGANTO PAVóN E: Historia del Trasplante Renal. Págs. 1-14. En M. González Martín y J. García Buitrón. Trasplante Renal. Grupo Aula Médica S.A. Madrid 2000.
89. COOPER DKC, TANIGUCHI S.: Historia del Xenotrasplante Clinico. Pags. 103-111. En Xenotrasplante. Arias M, Gómez-Fleitas M y De Francisco ALM. Editorial Sandoz Pharma S.A.R. Barcelona 1996.
90. MAñEZ R: Xenotrasplante de primate en humanos. Págs. 135-141. En Xenotrasplante. Arias M, Gómez-Fleitas M y De Francisco ALM. Editorial Sandoz Pharma S.A.R. Barcelona 1996.
91. COZZI E, WHITE DJG: Thegeneration of transgenic as potencial organ donors for humans. Nat Med. 1995; 57: 363-370.
92. PATIENCE C, TAKEUCHI Y, WEIS RA: Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997; 3: 282-286.